SCHEMBL24254622

SCHEMBL24254622

CC(C)C(=O)c1c(Br)cccc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.43
F2R P25116 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
PDE5A O76074 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
MIF P14174 1/20 0.38
TSHR P16473 1/20 0.38
PDE4A P27815 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
CYP2C19 P33261 1/20 0.38
BLM P54132 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL61847 0.86 CES2 (0.47) FFAR1MEN1KMT2AHTT
SCHEMBL29401587 0.85 PRNP (0.44) F2RMEN1KMT2AALDH1A1KDM4E
SCHEMBL5993493 0.83 HPGD (0.35) F2RMEN1KMT2AALDH1A1CYP1A2
SCHEMBL29480975 0.80 F2R (0.43) F2RMEN1KMT2AALDH1A1CYP1A2
SCHEMBL29480920 0.77 TSHR (0.53) F2RMEN1KMT2AALDH1A1CYP1A2
SCHEMBL28884085 0.77 F2R (0.43) F2RMEN1KMT2AALDH1A1GABRA1
SCHEMBL29573780 0.76 F2R (0.49) F2RMEN1KMT2AALDH1A1GAA
SCHEMBL2360603 0.76 F2R (0.49) F2RMEN1KMT2AALDH1A1GAA
SCHEMBL9901144 0.74 CA1 (0.57) FFAR1MEN1KMT2AALDH1A1CYP3A4
SCHEMBL10137794 0.74 FFAR1 (0.45) FFAR1MEN1KMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265083-A1 Heterocycle CDK Inhibitors And Their Use Thereof PRELUDE THERAPEUTICS INCORPORATED 2023-08-24 US disclosed
US-20230265083-A1 Heterocycle CDK Inhibitors And Their Use Thereof PRELUDE THERAPEUTICS INCORPORATED 2023-08-24 US disclosed
US-20230265083-A1 Heterocycle CDK Inhibitors And Their Use Thereof PRELUDE THERAPEUTICS INCORPORATED 2023-08-24 US disclosed
WO-2022035799-A1 HETEROCYCLE CDK INHIBITORS AND THEIR USE THEREOF PRELUDE THERAPEUTICS INCORPORATED (US) 2022-02-17 WO disclosed
WO-2022035799-A1 HETEROCYCLE CDK INHIBITORS AND THEIR USE THEREOF PRELUDE THERAPEUTICS INCORPORATED (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265083-A1 Heterocycle CDK Inhibitors And Their Use Thereof CDK3, CDK8, CDK9 FFAR1 4812/4885F2R 3909/4885MEN1 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.